These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 12043253)
1. [The role of "respiratory" fluoroquinolones in current antibacterial treatment of extrahospital pneumonia]. Sinopal'nikov AI Ter Arkh; 2002; 74(4):80-5. PubMed ID: 12043253 [No Abstract] [Full Text] [Related]
3. [Indications for use of fluoroquinolones in the treatment of community acquired pneumonia]. Mensa J; Martínez JA; Sánchez F; Marcos MA Enferm Infecc Microbiol Clin; 1998 Dec; 16 Suppl 2():31-5; discussion 47-52. PubMed ID: 10344096 [No Abstract] [Full Text] [Related]
4. Drug not considered a first-line agent. Lexchin J Can Fam Physician; 1998 Nov; 44():2376. PubMed ID: 9839049 [No Abstract] [Full Text] [Related]
5. New antibiotic approved for community-acquired infections. Nurse Pract; 1998 Jan; 23(1):94. PubMed ID: 9470200 [No Abstract] [Full Text] [Related]
6. Newer fluoroquinolones and the management of respiratory tract infections. Karchmer AW Clin Infect Dis; 2000 Aug; 31 Suppl 2():S15. PubMed ID: 10984322 [No Abstract] [Full Text] [Related]
7. [Treatment of pneumonia in a community]. Lecocq P; Mouton Y Rev Prat; 1993 Feb; 43(4):475-9. PubMed ID: 8341915 [No Abstract] [Full Text] [Related]
8. Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther; 2000 Feb; 42(1072):15-7. PubMed ID: 10705891 [No Abstract] [Full Text] [Related]
9. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. File TM Clin Infect Dis; 2004 Sep; 39 Suppl 3():S159-64. PubMed ID: 15546111 [TBL] [Abstract][Full Text] [Related]
10. The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia. Press RA Pharmacotherapy; 2001 Jul; 21(7 Pt 2):100S-104S. PubMed ID: 11446520 [TBL] [Abstract][Full Text] [Related]
15. Guideline-recommended antibiotics in community-acquired pneumonia: not perfect, but good. Sharpe BA Arch Intern Med; 2009 Sep; 169(16):1462-4. PubMed ID: 19752402 [No Abstract] [Full Text] [Related]
16. Empiric antibiotic prescribing for patients with community-acquired pneumonia: where can we improve? Buising KL; Thursky KA; Black JF; Macgregor L; Street AC; Kennedy MP; Brown GV Intern Med J; 2008 Mar; 38(3):174-7. PubMed ID: 18290813 [TBL] [Abstract][Full Text] [Related]
17. The role of host-pathogen interactions in chronic obstructive pulmonary disease exacerbations is unclear. Philpot R Intern Med J; 2007 Dec; 37(12):840; author reply 804-1. PubMed ID: 18028094 [No Abstract] [Full Text] [Related]
18. [Initial empiric treatment of pneumonia and the new antibiotics]. Parent M Union Med Can; 1994 Jan; 123(1):14-8. PubMed ID: 8109061 [No Abstract] [Full Text] [Related]
19. Should fluoroquinolones be first-line antibiotics in the treatment of community-acquired pneumonia in areas with high incidence of tuberculosis? Hsueh PR J Microbiol Immunol Infect; 2007 Oct; 40(5):386-7. PubMed ID: 17932596 [No Abstract] [Full Text] [Related]
20. Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones. Schriger DL; Hoffman JR; Cooper RJ; Gupta M J Emerg Med; 2007 Aug; 33(2):197; discussion 197. PubMed ID: 17692777 [No Abstract] [Full Text] [Related] [Next] [New Search]